Key facts
- Illudent’s last known valuation is $17.2M (Aug 2025).
- It has raised $4.4M across 1 recorded rounds; the latest was Seed Round ($3.2M) in Aug 2025.
- Notable investors include Ulu Ventures, SeedFolio.
- Illudent has filed 1 Form D with the SEC, most recently Aug 2025 ($3.2M sold to 11 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Illudent
Funding rounds
1 roundsAbout Illudent
Operator of a precision oncology therapy intended to treat solid tumors through targeted small-molecule intervention. The company offers a first-in-class drug candidate that exploits tumor-specific sensitivity in cancers deficient in nucleotide-excision repair, enabling oncologists to treat patients with greater precision while minimizing harm to healthy cells.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2016
- Employees
- 3
- Website
- illudent.com/
- Ownership
- Privately Held (backing)
Illudent doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Illudent shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Illudent in its N-PORT filings yet. We sweep new filings monthly.